U.S. markets closed

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4100+0.0100 (+0.42%)
At close: 4:00PM EDT
2.4100 0.00 (0.00%)
After hours: 04:13PM EDT

Outlook Therapeutics, Inc.

Building F
Suite 320 485 Route 1 South
Iselin, NJ 08830
United States
609 619 3990

Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Ralph H. ThurmanIndependent Exec. ChairmanN/AN/A1949
Mr. Lawrence A. Kenyon CPACFO, Treasurer, Company Sec. & Director562.88kN/A1966
Mr. Terry DagnonChief Operating Officer159.68kN/A1962
Mr. Jeffrey EvansonChief Commercial Officer159.68kN/A1969
Mr. C. Russell Trenary IIIPres, CEO & DirectorN/AN/A1958
Rick GregoryDirector of Marketing & CommunicationsN/AN/AN/A
Dr. Balu N. BalasubramanianAdvisorN/AN/AN/A
Ms. Elizabeth A. YamashitaAdvisorN/AN/A1961
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Corporate Governance

Outlook Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.